bicycle therapeutics

Bicycle Therapeutics is

developing bicyclic peptides

(Bicycles®) with antibody-

like binding, small molecule

tissue penetration and

excretion through the

kidneys

 

Bicycles are a new treatment modality combining the therapeutic benefits of antibodies, small molecules and peptides within one molecule. Bicycles exhibit the affinity and exquisite target specificity associated with antibodies, allowing intractable drug targets to be modulated often through interruption of protein-protein interactions. Bicycles’ small size enables rapid and deep tissue penetration, allowing tissues and tumours to be targeted from within. Bicycles’ peptidic nature provides, a “tuneable” pharmacokinetic half-life and a renal route of clearance, avoiding the liver and gastrointestinal tract toxicity often seen with other drug modalities.

 

Bicycles can be used as stand-alone therapeutic entities or coupled to deliver a variety of therapeutic payloads; Bicycle Therapeutics’ initial internal focus is to use Bicycles to selectively deliver toxins to tumours as Bicycle Drug Conjugates (BDCs). The company is also engaging in a range of collaborative models to help realize the full potential of the Bicycle technology for the development of therapeutics.

Bicycle Therapeutics

news

 

Press Release 23 May 2016

Bicycle Therapeutics establishes US Operations and appoints Rosamond Deegan, MBA, as President and Chief Business Officer More

 

Press Release 5 May 2016

Bicycle Therapeutics strengthens product development capabilities with key leadership appointments More 

 

Press Release 21 September 2015

Bicycle Therapeutics announces appointment of CEO More

 

Press Release 14 October 2014

Bicycle Therapeutics announces £20M ($32M) million financing for drug development More

 

Press Release 5 September 2013 Bicycle Therapeutics and ThromboGenics form an alliance to develop bicycle peptide inhibitors for the treatment of ophthalmic diseases More

 

Press Release 1 June 2013 Bicycle Therapeutics announces expansion of management team with appointments of CSO and Business Development Director More

 

Press Release 10 Dec 2012 Bicycle Therapeutics announces £3.75 million financing for drug discovery More

events